Total Payments
$243,806
2024 Payments
$6,791
Companies
5
Transactions
126
Medicare Patients
38,073
Medicare Billing
$1.5M
Payment Breakdown by Category
Consulting$208,495 (85.5%)
Research$35,175 (14.4%)
Food & Beverage$136.22 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $208,495 | 65 | 85.5% |
| Unspecified | $35,175 | 60 | 14.4% |
| Food and Beverage | $136.22 | 1 | 0.1% |
Payments by Type
General
$208,631
66 transactions
Research
$35,175
60 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $206,725 | 63 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $35,175 | 60 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $1,600 | 1 | $0 (2021) |
| Astellas Pharma Inc | $170.00 | 1 | $0 (2020) |
| HEARTFLOW, INC. | $136.22 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,791 | 12 | Regeneron Pharmaceuticals, Inc. ($6,655) |
| 2023 | $33,365 | 12 | PFIZER INC. ($22,850) |
| 2022 | $30,665 | 10 | PFIZER INC. ($30,200) |
| 2021 | $35,245 | 25 | PFIZER INC. ($30,025) |
| 2020 | $67,095 | 32 | PFIZER INC. ($61,170) |
| 2019 | $34,150 | 25 | PFIZER INC. ($27,585) |
| 2018 | $36,495 | 10 | PFIZER INC. ($34,895) |
All Payment Transactions
126 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $110.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 11/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $165.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 11/12/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $136.22 | General |
| Category: Coronary | ||||||
| 10/08/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $275.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 09/17/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $825.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 08/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $385.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 07/09/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $55.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 06/11/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $110.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 05/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $55.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 03/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $165.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 02/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $275.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 01/09/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,235.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 12/26/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,275.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 12/12/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,140.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $40.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,380.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 09/05/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $220.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 08/15/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $460.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 05/09/2023 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2023 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $7,735.00 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2023 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $6,125.00 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2023 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $4,660.00 | General |
| Category: ONCOLOGY | ||||||
| 01/24/2023 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $3,830.00 | General |
| Category: ONCOLOGY | ||||||
| 01/24/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $75.00 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2022 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $345.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES | Regeneron Pharmaceuticals, Inc. | $23,230 | 35 |
| A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer | Regeneron Pharmaceuticals, Inc. | $6,265 | 8 |
| A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $3,780 | 16 |
| A Phase 1 Study to Investigate the Safety and Pharmacokinetics of REGN2810 Anti-PD-1 in Japanese Patients With Advanced Malignancies | Regeneron Pharmaceuticals, Inc. | $1,900 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 56 | 7,612 | 13,626 | $2.3M | $317,889 |
| 2022 | 64 | 9,914 | 13,288 | $2.8M | $400,389 |
| 2021 | 61 | 11,055 | 11,912 | $3.1M | $442,196 |
| 2020 | 67 | 9,492 | 10,146 | $2.4M | $366,704 |
Total Patients
38,073
Total Services
48,972
Medicare Billing
$1.5M
Procedure Codes
273
All Medicare Procedures & Services
273 procedure records from CMS Medicare Utilization — Page 11 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 73590 | X-ray of lower leg, 2 views | Facility | 2020 | 62 | 69 | $3,848 | $535.18 | 13.9% |
| 76536 | Ultrasound of head and neck | Facility | 2020 | 19 | 19 | $2,755 | $502.88 | 18.3% |
| 73080 | X-ray of elbow, minimum of 3 views | Facility | 2020 | 62 | 63 | $2,961 | $486.08 | 16.4% |
| 73610 | X-ray of ankle, minimum of 3 views | Facility | 2020 | 55 | 60 | $3,055 | $467.95 | 15.3% |
| 73110 | X-ray of wrist, minimum of 3 views | Facility | 2020 | 51 | 60 | $2,520 | $451.45 | 17.9% |
| 72100 | X-ray of lower and sacral spine, 2 or 3 views | Facility | 2020 | 37 | 37 | $2,758 | $392.69 | 14.2% |
| 73060 | X-ray of upper arm, minimum of 2 views | Facility | 2020 | 51 | 52 | $2,704 | $386.72 | 14.3% |
| 71046 | X-ray of chest, 2 views | Office | 2020 | 17 | 17 | $2,550 | $384.90 | 15.1% |
| 71045 | X-ray of chest, 1 view | Office | 2020 | 35 | 36 | $1,512 | $316.29 | 20.9% |
| 73090 | X-ray of forearm, 2 views | Facility | 2020 | 39 | 42 | $1,764 | $306.95 | 17.4% |
| 73560 | X-ray of knee, 1 or 2 views | Facility | 2020 | 35 | 37 | $1,110 | $290.68 | 26.2% |
| 74019 | X-ray of abdomen, 2 views | Facility | 2020 | 27 | 27 | $2,025 | $272.24 | 13.4% |
| 73522 | X-ray of both hips with pelvis, 3-4 views | Facility | 2020 | 18 | 18 | $2,340 | $234.28 | 10.0% |
| 72110 | X-ray of lower and sacral spine, minimum of 4 views | Facility | 2020 | 17 | 17 | $1,326 | $195.36 | 14.7% |
| 73020 | X-ray of shoulder, 1 view | Facility | 2020 | 20 | 20 | $1,158 | $156.18 | 13.5% |
| 73564 | X-ray of knee, 4 or more views | Facility | 2020 | 14 | 14 | $950.00 | $127.81 | 13.5% |
| 72040 | X-ray of spine of neck, 2 or 3 views | Facility | 2020 | 13 | 13 | $871.00 | $126.78 | 14.6% |
| 72070 | X-ray of middle spine, 3 views | Facility | 2020 | 13 | 13 | $914.00 | $125.53 | 13.7% |
| 76376 | 3d radiographic procedure | Facility | 2020 | 13 | 13 | $1,950 | $120.53 | 6.2% |
| 73501 | X-ray of hip with pelvis, 1 view | Facility | 2020 | 13 | 13 | $1,300 | $117.68 | 9.1% |
| 71100 | X-ray of ribs of one side of body, 2 views | Facility | 2020 | 12 | 12 | $804.00 | $105.86 | 13.2% |
| 73600 | X-ray of ankle, 2 views | Facility | 2020 | 11 | 14 | $518.00 | $105.11 | 20.3% |
| 72020 | X-ray of spine, 1 view | Facility | 2020 | 11 | 12 | $564.00 | $61.68 | 10.9% |
About Dr. Michael Reiter, D.O
Dr. Michael Reiter, D.O is a Diagnostic Radiology healthcare provider based in Stony Brook, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1598960916.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Reiter, D.O has received a total of $243,806 in payments from pharmaceutical and medical device companies, with $6,791 received in 2024. These payments were reported across 126 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($208,495).
As a Medicare-enrolled provider, Reiter has provided services to 38,073 Medicare beneficiaries, totaling 48,972 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 273 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Stony Brook, NY
- Active Since 06/16/2007
- Last Updated 10/30/2014
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1598960916
Products in Payments
- LORBRENA (Drug) $136,385
- BAVENCIO (Drug) $59,790
- LIBTAYO (Biological) $33,575
- TALZENNA (Drug) $10,550
- KEYTRUDA (Biological) $1,600
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $1,600
- FFRct (Device) $136.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Stony Brook
Dr. Kevin Baker, Md, MD
Diagnostic Radiology — Payments: $1.0M
Diagnostic Radiology $1.0M
Dr. Steven West, M.d, M.D
Diagnostic Radiology — Payments: $234,190
Diagnostic Radiology $234,190
Dr. Lev Bangiyev, Do, DO
Diagnostic Radiology — Payments: $129,200
Diagnostic Radiology $129,200
Annapurneswara Chimpiri, Md, MD
Diagnostic Radiology — Payments: $30,887
Diagnostic Radiology $30,887
Charles Lugo, M.d, M.D
Diagnostic Radiology — Payments: $22,881
Diagnostic Radiology $22,881
Dr. Vladimir Sheynzon, Md, MD
Diagnostic Radiology — Payments: $11,777
Diagnostic Radiology $11,777